ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522…

2024 ESMO Annual Meeting Insights Hub

S. Tolaney, H. Rugo

The 2023 ASCO®/CAP Guideline Update on HER2 Testing/Classification: …

Shabnam Jaffer

ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, …

2024 ESMO Annual Meeting Insights Hub

V. Kaklamani

Cancer Screening in Primary Care: An Evidence-Based Review of Outpat…

UNC Lineberger Comprehensive Cancer Center

N. Robertson

NATALEE Trial Impact on eBC: Ribociclib + ET as Adjuvant Treatment i…

Jan-Willem Henning

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Total Health

R. O'Regan

Optimizing Adjuvant Treatment in High-Risk HR+/HER2- eBC: Patient Se…

Wassim Mchayleh

ESMO 2024 Summary: Tailoring Therapy in TNBC and Beyond

2024 ESMO Annual Meeting Insights Hub

L. Carey

Perspectives on the Effects of Time Toxicity in Breast Cancer Treatm…

Kathryn Post

J. Hutchinson